Iron out KRAS-driven cancer

Guang Lei, Boyi Gan

Research output: Contribution to journalComment/debatepeer-review


How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med. leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.

Original languageEnglish (US)
Article numbere20212166
JournalJournal of Experimental Medicine
Issue number4
StatePublished - Apr 4 2022

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Iron out KRAS-driven cancer'. Together they form a unique fingerprint.

Cite this